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Background: Endurance trained athletic healthy volunteers (Athl-HV) and
type 2 diabetes patients (T2D) have higher levels of lipids in their skele-
tal myocytes compared to healthy controls. Despite apparently similar
metabolic storage, they are at opposite ends of insulin sensitivity and
cardio-metabolic risk.
Purpose: We investigated if the degree of saturation of the IntraMyoCel-
lular Lipids (IMCL) will differentiate Athl-HV from T2D; and explored if an
exercise intervention will induce changes in the IMCL saturation.
Methods: Male, age matched Athl-HV and T2D were enrolled
(n=25/group). Athl-HV had ≥5 years endurance training, T2D were seden-
tary. Subjects were studied at baseline and after an exercise intervention
(4 week deconditioning in Athl-HV and supervised bike training at ≥65%
of peakVO2, 5 hours/week x 8 weeks in T2D). All subjects underwent
cardio-pulmonary exercise testing (CPET), blood sampling for insulin sen-
sitivity (QUICKI*) and single voxel 1H-magnetic resonance spectroscopy
(1H-MRS) of the right vastus lateralis. 1H-MRS was acquired on 3T Philips
Achieva with a 16-channel coil, point-resolved spectroscopy, variable pulse
power and optimized relaxation delay water suppression and analysed in
LCModel. We derived fractional lipid mass (fLM) and fractions of saturated
(fSL) and unsaturated (fUL) lipids. Data were analysed by t tests, shown
as mean±SEM, statistical signiﬁcance p<0.05.
Results: CPET and insulin sensitivity are presented in Table 1. T2D
had higher fLM in the skeletal muscle compared to Athl-HV, at base-
line (p=0.003) and after the exercise intervention (p=0.009), Figure 1A.
At baseline, T2D had a different phenotype with a lower fSL and higher
fUL compared to Athl-HV (82±3 vs 88±1% and 18±3 vs 12±1%, p=0.02
for both). Whilst deconditioning did not attract any signiﬁcant changes in
either fSL or fUL in Athl-HV (88±1 to 86±1% and 12±1 to 14±1, p=0.2),
in contrast, with exercise training T2D signiﬁcantly increased fSL (82±3 to
88±1%) and decreased their fUL (18±3 to 12±1%) (both p=0.01). Figure
1B and 1C.
Conclusion: We demonstrate for the ﬁrst time, in vivo, signiﬁcant differ-
ences in the IMCL amount and saturation between Athl-HV and T2D. IMCL
saturation was changed by exercise training in T2D to mirror the phenotype
seen in Athl-HV uncovering a new, independent biomarker of improved
cardio-metabolic health.
CPET and insulin sensitivity results
Athl-HV Baseline Athl-HV Deconditioning p value T2D Baseline T2D After Training p value
VO2 peak, (mL/kg/min) 45.0±0.9† 41.7±0.9‡ <0.0001 23.6±0.6† 30.3±0.6‡ <0.0001
QUICKI* 0.346±0.002† 0.343±0.003‡ 0.2 0.308±0.004† 0.317±0.004‡ 0.02
*QUICKI: Quantitative Insulin Sensitivity Check Index; †Athl-HV vs T2D at baseline p≤0.001, ‡Athl-HV vs T2D after exercise intervention p≤0.001.
Figure 1
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